Zacks Investment ResearchT3·16d ago
ZBH Zimmer Biomet Holdings, Inc.
XNYS
96.39
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ZBH
$96.39
—
Key stats
$96.39
After hours
$96.97
+0.60%
- 52-Week Range
- $79.12 – $103.70
- YTD
- +7.08%
- IV Rank (30D)
- 64.84
- Straddle Price
- $7.55
- P/C Vol Ratio
- 3.22
- Market Cap
- $18.3B
- Open
- $95.33
- Day Range
- $95.10 – $96.74
- Volume
- 2,169,884
- Prev Close
- $96.06
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.00% |
| Beta vs SPY | 0.80 |
| Cost of Equity (CAPM) | 8.98% (VRP-adj) |
| WACC | 8.23% |
| Volatility Risk Premium | +28.8pp (IV − HV30) |
| Effective Tax Rate | 13.6% |
| Rev. Growth (YoY, DCF input) | +8.8% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.09 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.1B |
| Return on Equity (TTM) | 6.4% |
| Book / Price | 66.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 69.9% |
| FCF Margin (TTM) | 12.5% |
| Debt / Equity | 0.50 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +6.9% (reverse-DCF on current price) |
| SMA 50 | $95.06 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $92.75 |
| Bollinger Width / SMA20 | 16.3% (drives anchor stability) |
| Net Debt | $5.9B |
| Market Cap | $19B |
Peers used for multiples: ABT, GEHC, MDT
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
61%
20-Day Fair Value
≈ by Nov 26, 2026
$97.39
α +1.0%
rank 46%
conviction
61%
40-Day Fair Value
≈ by Dec 25, 2026
$99.15
α +2.9%
rank 51%
conviction
83%
60-Day Fair Value
≈ by Jan 25, 2027
$98.22
α +1.9%
rank 50%
conviction
61%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $110.84 | 24% | |
| DDM (Gordon) | $25.35 | 0% | |
| Peer P/E | $103.88 | 7% | median 23.2× · 3 peers |
| Peer EV/EBITDA | $171.70 | 7% | median 14.7× · 3 peers |
| Peer P/B | $190.27 | 7% | median 3.0× · 3 peers |
| Peer P/S | $152.12 | 7% | median 3.2× · 3 peers |
| Market Anchor (SMA50) | $95.06 | 32% | stability 68% (BB-width) |
| Options Expected (B-L 30d) | $96.08 | 15% | 13 strikes · skew -0.54 |
As of 2026-10-28 · updated
Related
About
- Industry (SIC)
- ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES (3842) · industry map
- Exchange
- XNYS
- Market Cap
- $18.3B
- Employees
- 17,000
- List Date
- 2001-08-07
- CIK
- 0001136869
- Next Earnings
- 2026-11-04 (Pre-Market)
- EPS Forecast
- $1.88
- Headquarters
- Warsaw, IN
- Homepage
- https://www.zimmerbiomet.com
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.33% | -4.73% | 0.05% | 3.47% | 4.81% | -3.28% | 0.11% |
| Feb | 5.95% | 2.58% | -3.08% | -2.27% | -3.55% | 14.17% | 2.30% |
| Mar | -2.03% | 3.03% | 5.83% | 6.43% | 7.40% | -9.12% | 1.92% |
| Apr | 10.72% | -5.46% | 8.12% | -7.30% | -8.29% | -9.45% | -1.94% |
| May | -5.40% | -0.36% | -8.28% | -3.69% | -9.48% | -0.69% | -4.65% |
| Jun | -3.25% | -11.92% | 14.32% | -4.06% | 0.11% | 3.80% | -0.17% |
| Jul | 0.17% | 2.91% | -3.06% | 5.09% | -2.56% | 11.16% | 2.29% |
| Aug | -7.71% | -3.13% | -9.94% | 3.91% | 17.08% | 3.16% | 0.56% |
| Sep | -2.99% | -2.11% | -6.05% | -7.08% | -6.20% | -10.63% | -5.84% |
| Oct | -4.25% | 5.62% | -6.29% | -0.39% | 1.69% | 9.46%* | 0.97% |
| Nov | -17.96% | 7.39% | 10.70% | 4.50% | -2.36% | -- | 0.45% |
| Dec | 6.05% | 3.36% | 3.16% | -4.41% | -5.11% | -- | 0.61% |
| Total | -21.15% | -4.42% | 2.12% | -6.93% | -9.03% | 5.08% | -5.72% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $93.13
SMA 50: $95.00
SMA 200: $91.56
Current: $96.39
EMA 12: $95.50
EMA 26: $94.41
MACD: 1.0917 | Signal: 0.6049
BULLISH
ADX (14): 18.79
RANGE
+DI: 24.95
−DI: 19.75
Momentum Oscillators
RSI (14): 56.27
NEUTRAL
Stoch %K: 76.79
Stoch %D: 84.26
Williams %R: -26.83
Volume & Volatility
BB Upper: $100.09
BB Lower: $86.17
NEUTRAL
OBV: 47,037,323
Vol SMA 20: 1,939,973
Vol ROC: 14.79%
ATR: $2.40
True Range: $1.64
HV 20: 28.1%
HV 30: 28.9%
HV 60: 27.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-30T00:00:00 – 2026-10-28T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Confidence Level: 7/10 (BULLISH)
Key Drivers: Positive news sentiment, technical momentum, and low volatility
Primary Risks: High IV rank, options market pricing a significant move
Investment Thesis: Zimmer Biomet Holdings Inc. (ZBH) is poised for further upside due to its strong fundamentals in the orthopedic surgery industry, positive recent news headlines, and relatively low volatility.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, highlighting the company's growth potential and market trends in the industry.
Technical Analysis
Trend Direction: Medium-term (1-3 months) uptrend
Support/Resistance Levels:
- Lower Bollinger Band: $95.60
- Middle Line: $98.94
- Upper Bollinger Band: $102.28
- MACD signal line: -0.15
Momentum Signals:
- RSI interpretation: Neutral (58.98)
- MACD signal: Bullish momentum
- Bollinger Bands position: Squeeze
Volume Analysis: Volume is relatively low, indicating a lack of institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting the company's growth potential and market trends in the industry.
Sentiment Assessment: Positive (4/5)
Catalyst Identification: No specific earnings or product launch catalysts identified, but ongoing positive sentiment and momentum could drive further upside.
Market Narrative: The news headlines align with the technical signals, indicating a strong fundamental narrative driving the stock's recent move.
Risk & Volatility Assessment
Beta Interpretation: Low risk (beta <0.8)
Volatility Regime: Relatively low volatility
Options Market Signals:
- IV rank: 69.4% (Medium)
- Put/Call Volume Ratio: 0.61 (Bullish sentiment)
- Open Interest: 2,630 calls vs 870 puts
Downside Protection: Support levels at $95.60 and $98.94.
Market Context & Positioning
Sector Performance: The healthcare sector is performing well, with ZBH outperforming the broader market.
Institutional Activity: Low institutional interest indicated by relatively low volume.
Correlation Analysis: ZBH has a low correlation (0.08) to the S&P 500, suggesting it may be less sensitive to market volatility.
Relative Valuation: The stock is positioned within its trading range, indicating potential for further upside.
Key Levels & Action Items
Critical Price Levels:
- Support at $95.60 and $98.94
- Resistance at $102.28
Breakout/Breakdown Levels: None identified
Time-Sensitive Catalysts: No specific earnings or product launch catalysts identified, but ongoing positive sentiment and momentum could drive further upside.
Risk Management: Stop-loss levels at $95.60 and position sizing considerations based on risk tolerance.
Generated
News
All ZBH news →
Zacks Investment ResearchT3·21d ago
Zacks Investment ResearchT3·22d ago
Zacks Investment ResearchT3·1mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·4mo ago
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·6mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
17 of 23 under expected move
Avg Expected Move
6.56%
Avg Actual Move
5.00%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-05 | Pre-Market | 6.31% | 0.52% | 0.08x | Within |
| 2021-05-04 | Pre-Market | 5.11% | 2.82% | 0.55x | Within |
| 2021-08-03 | Pre-Market | 5.52% | 5.71% | 1.03x | Exceeded |
| 2021-11-04 | Pre-Market | 8.14% | 7.39% | 0.91x | Within |
| 2022-02-07 | Pre-Market | 7.42% | 9.09% | 1.23x | Exceeded |
| 2022-04-28 | Pre-Market | 7.91% | 1.41% | 0.18x | Within |
| 2022-08-02 | Pre-Market | 6.24% | 3.92% | 0.63x | Within |
| 2022-11-02 | Pre-Market | 6.73% | 3.71% | 0.55x | Within |
| 2023-02-03 | Pre-Market | 5.65% | 1.60% | 0.28x | Within |
| 2023-05-02 | Pre-Market | 5.11% | 3.01% | 0.59x | Within |
| 2023-08-01 | Pre-Market | 5.21% | 4.26% | 0.82x | Within |
| 2023-11-07 | Pre-Market | 6.59% | 3.08% | 0.47x | Within |
| 2024-02-08 | Pre-Market | 5.68% | 3.54% | 0.62x | Within |
| 2024-05-02 | Pre-Market | 6.15% | 0.92% | 0.15x | Within |
| 2024-08-07 | Pre-Market | 6.09% | 3.43% | 0.56x | Within |
| 2024-10-30 | Pre-Market | 7.80% | 5.71% | 0.73x | Within |
| 2025-02-06 | Pre-Market | 5.54% | 5.14% | 0.93x | Within |
| 2025-05-05 | Pre-Market | 6.50% | 11.62% | 1.79x | Exceeded |
| 2025-08-07 | Pre-Market | 6.86% | 7.99% | 1.16x | Exceeded |
| 2025-11-05 | Pre-Market | 8.09% | 15.15% | 1.87x | Exceeded |
| 2026-02-10 | Pre-Market | 6.83% | 1.86% | 0.27x | Within |
| 2026-04-28 | Pre-Market | 7.10% | 10.57% | 1.49x | Exceeded |
| 2026-08-05 | Pre-Market | 8.22% | 2.45% | 0.30x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ZBH Options Activity & IV Rank
ZBH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 37.5%
7-DTE IV: —
Expected Move: $7.55
7-DTE Move: $7.55
Days to Exp: 23 (2026-11-20)
Options Flow
Call Volume: 9
Put Volume: 29
P/C Volume: 3.222
BEARISH
Call OI: 1,068
Put OI: 2,349
P/C OI: 2.199
Total OI: 3,417
ATM Options Pricing
ATM Call: $4.53
ATM Put: $3.02
Call %: 4.7%
Put %: 3.1%
Chain Summary
Chain Volume: 971
Chain OI: 11,088
Last Updated: 10/28/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
44%
vs own history
GEX tilt
-0.13
OI-weighted, today
Vanna tilt
+0.69
δ-sensitivity to IV
Charm tilt
-0.82
δ-decay vs time
Vanna tilt +0.69: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.82: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 28 ATM contracts, 8k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
100%
+23.7
pts
EXTREME
as of Oct 26 · ATM 38.3% / Wing 62.0%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)64.8MediumOct 28
Straddle Price (30 DTE)$7.55Oct 28
Beta Analysis
Risk Metrics
Beta: 0.1171
Alpha: -0.81%
Correlation: 0.0455
R-Squared: 0.2%
Stock Volatility: 32.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ZBH
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $299.4M | #102 of 6285 | +152.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $75.7M | #225 of 1945 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $19.1M | #1161 of 3716 | new | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $3.1M | #585 of 997 | +6.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1.1M | #1666 of 4729 | +0.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ZBH Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 196,525,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
13 filers$33.87M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.37M | 21.76% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $7.36M | 21.73% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $6.41M | 18.94% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $3.10M | 9.15% | 2026-06-30 |
| 5 | Walleye Trading LLC | $2.99M | 8.82% | 2026-06-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $1.93M | 5.69% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $1.62M | 4.79% | 2025-09-30 |
| 8 | Walleye Capital LLC | $1.07M | 3.15% | 2026-06-30 |
| 9 | Point72 Asset Management, L.P. | $757.59K | 2.24% | 2026-06-30 |
| 10 | Two Sigma Investments, LP Custodian | $533.76K | 1.58% | 2026-06-30 |
| 11 | TUDOR INVESTMENT CORP ET AL | $499.32K | 1.47% | 2026-06-30 |
| 12 | Simplex Trading, LLC Custodian | $146.35K | 0.43% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $86.09K | 0.25% | 2026-06-30 |
14 filers$34.30M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $9.85M | 28.71% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $9.37M | 27.30% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $3.09M | 9.01% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $2.94M | 8.56% | 2026-06-30 |
| 5 | Walleye Trading LLC | $2.45M | 7.15% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $1.86M | 5.42% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $1.78M | 5.19% | 2025-09-30 |
| 8 | CAPSTONE INVESTMENT ADVISORS, LLC | $835.07K | 2.43% | 2026-06-30 |
| 9 | Two Sigma Investments, LP Custodian | $783.42K | 2.28% | 2026-06-30 |
| 10 | Walleye Capital LLC | $490.71K | 1.43% | 2026-06-30 |
| 11 | Point72 Asset Management, L.P. | $439.06K | 1.28% | 2026-06-30 |
| 12 | LPL Financial LLC Custodian | $215.22K | 0.63% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $103.31K | 0.30% | 2026-06-30 |
| 14 | Lido Advisors, LLC | $103.31K | 0.30% | 2026-06-30 |
ZBH Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Gary Craig Campbell | President, Americas | Mixed | +2,174 | $88.42 | -$124.8K | EDGAR |
| 2026-10-02 | Arthur J Higgins | Director | Grant (A) | +306 RSU | — | EDGAR | |
| 2026-10-02 | Maria Teresa Hilado | Director | Grant (A) | +375 RSU | — | EDGAR | |
| 2026-10-02 | Sreelakshmi Kolli | Director | Grant (A) | +173 RSU | — | EDGAR | |
| 2026-10-02 | Devdatt Kurdikar | Director | Grant (A) | +173 RSU | — | EDGAR | |
| 2026-10-02 | Louis Shapiro | Director | Grant (A) | +153 RSU | — | EDGAR | |
| 2026-10-02 | Michael J. Farrell | Director | Grant (A) | +417 RSU | — | EDGAR | |
| 2026-10-02 | Robert Hagemann | Director | Grant (A) | +306 RSU | — | EDGAR | |
| 2026-09-15 | Kevin R Thornal | Grp Pres-Global Business | Sell (S) | −5,691 | $92.95 | -$529.0K | EDGAR |
| 2026-09-09 | Chad F Phipps | See remarks below. | Sell (S) | −3,000 | $98.35 | -$295.1K | EDGAR |
| 2026-08-05 | Chintan Desai | President, APAC | Grant (A) | +10,168 RSU | — | EDGAR | |
| 2026-08-04 | Kevin R Thornal | Grp Pres-Global Business | Mixed | +5,691 | $92.68 | -$395.4K | EDGAR |
| 2026-07-02 | Louis Shapiro | Director | Grant (A) | +158 RSU | — | EDGAR | |
| 2026-07-02 | Arthur J Higgins | Director | Grant (A) | +317 RSU | — | EDGAR | |
| 2026-07-02 | Michael J. Farrell | Director | Grant (A) | +432 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ZBH Insider Holdings
19 insiders · @ $96.39
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ivan Tornos | Chairman, President and CEO | 78,602 | $7.58M | $0 | 29 | 2026-03-10 |
| 2 | Suketu Upadhyay | Exec VP, CFO | 69,485 | $6.70M | $0 | 25 | 2026-03-10 |
| 3 | Chad F Phipps | See remarks below. | 65,231 | $6.29M | -$33.82M | 77 | 2026-09-09 |
| 4 | Wilfred Van Zuilen | Group Pres, EMEA | 30,652 | $2.95M | -$55.9K | 17 | 2026-03-10 |
| 5 | Sang Yi | Group President, Asia Pacific | 27,251 | $2.63M | -$5.68M | 51 | 2026-06-02 |
| 6 | Mark Bezjak | President, Americas | 13,772 | $1.33M | $0 | 7 | 2025-03-07 |
| 7 | Rachel Ellingson | Chief Administrative Officer | 11,906 | $1.15M | $0 | 14 | 2025-02-24 |
| 8 | Lori Winkler | SVP and CHRO | 10,224 | $985.5K | -$711.5K | 24 | 2026-03-16 |
| 9 | Paul A Stellato | VP, Controller, CAO | 5,864 | $565.2K | $0 | 17 | 2026-05-05 |
| 10 | Betsy J Bernard | Director | 5,271 | $508.1K | $615.8K | 75 | 2026-05-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ZBH Board & Officers
As of SEC filings through Oct 5, 2026Directors 10
- Arthur J Higgins · since Feb 12, 2007
- Betsy J Bernard · since Jan 8, 2009
- Michael J. Farrell · since Dec 11, 2014
- Maria Teresa Hilado · since Aug 3, 2018
- Syed A. Jafry · since Aug 3, 2018
- Robert Hagemann · listed since Oct 2019
- Sreelakshmi Kolli · since Feb 18, 2021
- Ivan Tornos · listed since Sep 2023
- Louis Shapiro · since Jan 5, 2024
- Devdatt Kurdikar · since Jun 20, 2024
Officers 11
- Ivan Tornos · Chairman, President and CEO · listed since Feb 2026
- Sang Yi · Group President, Asia Pacific · listed since Feb 2024
- Jehanzeb Noor · Senior Vice President, Chief Strategy, Innovation & Business Development Officer · since Mar 3, 2025
- Chad F Phipps · Senior Vice President, Chief Legal, Corporate Affairs and Secretary · listed since Feb 2026
- Chintan Desai · President, APAC · since Jul 13, 2026
- Brian Matthew Hatcher · President, Recon, SET, CMFT · since Oct 1, 2026
- Gary Craig Campbell · President, Americas · since Oct 1, 2026
- Lori Winkler · SVP and CHRO · since Mar 22, 2021
- Paul A Stellato · VP, Controller & CAO · since May 16, 2022
- Wilfred Van Zuilen · Group Pres, EMEA · listed since Feb 2024
- Kevin R Thornal · Grp Pres-Global Business · listed since Feb 2026
Changes in the last 10 years (49)
| Oct 1, 2026 | Gary Craig Campbell became President, Americas |
| Oct 1, 2026 | Brian Matthew Hatcher became President, Recon, SET, CMFT |
| Jul 13, 2026 | Chintan Desai became President, APAC |
| Apr 22, 2026 | The company announced the departure of Suketu Upadhyay as Exec. VP, CFO in an SEC filing |
| Feb 24, 2026 | Kevin R Thornal listed as Grp Pres-Global Business (previously Grp Pres-Global Bus.) in SEC filings |
| Feb 24, 2026 | Chad F Phipps listed as Senior Vice President, Chief Legal, Corporate Affairs and Secretary (previously Sr. VP/Gen Counsel/Secretary) in SEC filings |
| Feb 23, 2026 | Ivan Tornos listed as Chairman, President and CEO (previously President and CEO) in SEC filings |
| Jul 1, 2025 | Kevin R Thornal became Grp Pres-Global Bus. |
| May 20, 2025 | The company announced the departure of Mark Bezjak as President, Americas in an SEC filing |
| Mar 3, 2025 | Jehanzeb Noor became Senior Vice President, Chief Strategy, Innovation & Business Development Officer |
| Feb 19, 2025 | Rachel Ellingson listed as Chief Administrative Officer (previously SVP & Chief Strategy Officer) in SEC filings |
| Jun 20, 2024 | Devdatt Kurdikar became a director |
| Feb 22, 2024 | Wilfred Van Zuilen listed as Group Pres, EMEA (previously Pres, Europe, M. East & Africa) in SEC filings |
| Feb 22, 2024 | Sang Yi listed as Group President, Asia Pacific (previously President, Asia Pacific) in SEC filings |
| Jan 5, 2024 | Louis Shapiro became a director |
| Dec 13, 2023 | Mark Bezjak became President, Americas |
| Sep 6, 2023 | Ivan Tornos listed as President and CEO (previously Chief Operating Officer) in SEC filings |
| Sep 6, 2023 | Ivan Tornos first listed as a director in an SEC filing |
| Aug 17, 2023 | The company announced the departure of Bryan C Hanson from the board in an SEC filing |
| Aug 17, 2023 | The company announced the departure of Bryan C Hanson as President and CEO in an SEC filing |
| May 16, 2022 | Paul A Stellato became VP, Controller & CAO |
| Dec 7, 2021 | Ivan Tornos listed as Chief Operating Officer (previously Grp Pres Global Bus & Americas) in SEC filings |
| Dec 6, 2021 | Derek M Davis listed as Interim Controller & CAO (previously VP, Controller and CAO) in SEC filings |
| Oct 29, 2021 | The company announced the departure of Carrie Ann Nichol as VP, Controller & CAO in an SEC filing |
| Jun 1, 2021 | Wilfred Van Zuilen became Pres, Europe, M. East & Africa |
| Mar 22, 2021 | Lori Winkler became SVP and CHRO |
| Mar 1, 2021 | Rachel Ellingson listed as SVP & Chief Strategy Officer (previously SVP & Cso) in SEC filings |
| Feb 18, 2021 | Sreelakshmi Kolli became a director |
| Jan 4, 2021 | Rachel Ellingson became SVP & Cso |
| Feb 18, 2020 | Ivan Tornos listed as Grp Pres Global Bus & Americas (previously Group President, Orthopedics) in SEC filings |
| Oct 2, 2019 | Robert Hagemann first listed as a director in an SEC filing |
| Oct 2, 2019 | Gail Boudreaux first listed as a director in an SEC filing |
| Oct 1, 2019 | Carrie Ann Nichol became VP, Controller & CAO |
| Jul 1, 2019 | Suketu Upadhyay became Exec. VP, CFO |
| Jan 3, 2019 | Robert Hagemann reported in an SEC filing no longer being a director |
| Jan 3, 2019 | Gail Boudreaux reported in an SEC filing no longer being a director |
| Nov 1, 2018 | Ivan Tornos became Group President, Orthopedics |
| Aug 20, 2018 | Didier Deltort became President, EMEA |
| Aug 3, 2018 | Syed A. Jafry became a director |
| Aug 3, 2018 | Maria Teresa Hilado became a director |
| Aug 3, 2018 | Daniel P Florin listed as Exec. VP, CFO (previously Sr. VP, CFO) in SEC filings |
| Feb 14, 2018 | Daniel P Florin no longer listed as a director in SEC filings |
| Feb 14, 2018 | Daniel P Florin listed as Sr. VP, CFO (previously Interim CEO, Sr. VP, CFO) in SEC filings |
| Dec 20, 2017 | Aure Bruneau became Group President |
| Dec 19, 2017 | Bryan C Hanson became a director |
| Dec 19, 2017 | Bryan C Hanson became President and CEO |
| Aug 3, 2017 | Daniel P Florin listed as Interim CEO, Sr. VP, CFO (previously Sr. VP, CFO) in SEC filings |
| Aug 3, 2017 | Daniel P Florin first listed as a director in an SEC filing |
| Feb 10, 2017 | Robert D. Delp became President, Americas |
Not reported recently (19)
- Christopher B Begley · Last reported as a director in an SEC filing dated Apr 2, 2025
- Rachel Ellingson · Last reported as Chief Administrative Officer in an SEC filing dated Feb 24, 2025
- Michael W Michelson · Last reported as a director in an SEC filing dated May 14, 2024
- Derek M Davis · Last reported as Interim Controller & CAO in an SEC filing dated Mar 3, 2022
- Gail Boudreaux · Last reported as a director in an SEC filing dated Apr 2, 2021
- Didier Deltort · Last reported as President, EMEA in an SEC filing dated Mar 2, 2021
- Larry C Glasscock · Last reported as a director in an SEC filing dated May 12, 2020
- Aure Bruneau · Last reported as Group President in an SEC filing dated Nov 13, 2019
- Daniel P Florin · Last reported as Exec. VP, CFO in an SEC filing dated Jun 20, 2019
- Tony W. Collins · Last reported as VP, Controller and CAO in an SEC filing dated Aug 2, 2018
- Katarzyna Mazur-Hofsaess · Last reported as Pres., Eur., M. East & Afr. in an SEC filing dated May 23, 2018
- Jeffrey K. Rhodes · Last reported as a director in an SEC filing dated Apr 3, 2018
- Daniel E. Williamson · Last reported as Group President in an SEC filing dated Mar 22, 2018
- David A. Nolan Jr. · Last reported as Group President in an SEC filing dated Mar 22, 2018
- Robert D. Delp · Last reported as President, Americas in an SEC filing dated Mar 22, 2018
- Adam Rudolph Johnson · Last reported as Group President in an SEC filing dated Jun 27, 2017
- Cecil B Pickett · Last reported as a director in an SEC filing dated May 16, 2017
- David C Dvorak · Last reported as a director in an SEC filing dated May 1, 2017
- Paul Bisaro · Last reported as a director in an SEC filing dated Apr 4, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ZBH Proposed Insider Sales (Form 144)
Latest: 2026-09-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $824K notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Thornal Kevin R (1, $529K) · Phipps Chad F (1, $295K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-11 | Thornal Kevin R | Officer | 5,691 | $529.0K | 2026-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-04 | Phipps Chad F | Officer | 3,000 | $295.1K | 2026-09-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-16 | Upadhyay Suketu | Former Officer | 7,668 | $712.1K | 2026-07-16 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-06-24 | Upadhyay Suketu | Former Officer | 4,560 | $410.7K | 2026-06-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-29 | Yi Sang | Officer | 5,000 | $413.2K | 2026-05-29 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-19 | Upadhyay Suketu | Former Officer | 5,373 | $464.1K | 2026-05-19 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-12 | Upadhyay Suketu | Former Officer | 31,253 | $2.61M | 2026-05-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-12 | Winkler Lori | Officer | 2,650 | $250.8K | 2026-03-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-12 | Yi Sang | Officer | 1,000 | $96.5K | 2026-02-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-11 | Yi Sang | Officer | 1,200 | $124.3K | 2025-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-27
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-27 | 0001193125-26-242207 | EDGAR |
| 2026-05-12 | 0001193125-26-218098 | EDGAR |
| 2026-04-28 | 0001193125-26-183411 | EDGAR |
| 2026-04-28 | 0001193125-26-183430 | EDGAR |
| 2026-02-10 | 0001193125-26-043620 | EDGAR |
| 2026-01-12 | 0001193125-26-009895 | EDGAR |
| 2025-11-05 | 0001193125-25-265649 | EDGAR |
| 2025-10-07 | 0001193125-25-233473 | EDGAR |
| 2025-09-04 | 0001193125-25-196060 | EDGAR |
| 2025-08-07 | 0000950170-25-104527 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-20 | 0001193125-26-059853 | EDGAR |
| 2025-02-25 | 0000950170-25-026604 | EDGAR |
| 2024-02-23 | 0000950170-24-019353 | EDGAR |
| 2023-02-24 | 0000950170-23-004264 | EDGAR |
| 2022-02-25 | 0001564590-22-007160 | EDGAR |
| 2021-02-22 | 0001564590-21-007163 | EDGAR |
| 2020-02-21 | 0001564590-20-005657 | EDGAR |
| 2019-02-26 | 0001564590-19-004283 | EDGAR |
| 2018-02-27 | 0001564590-18-003549 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-01 | 0001193125-26-201710 | EDGAR |
| 2025-11-05 | 0001193125-25-266884 | EDGAR |
| 2025-08-07 | 0000950170-25-104989 | EDGAR |
| 2025-05-05 | 0000950170-25-063509 | EDGAR |
| 2024-10-30 | 0000950170-24-118959 | EDGAR |
| 2024-08-07 | 0000950170-24-092746 | EDGAR |
| 2024-05-02 | 0000950170-24-052097 | EDGAR |
| 2023-11-07 | 0000950170-23-060232 | EDGAR |
| 2023-08-01 | 0000950170-23-036456 | EDGAR |
| 2023-05-02 | 0000950170-23-016663 | EDGAR |
ETF Holders
255 ETFs hold ZBH
25 shown · $3.30B total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $537.0M | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.03% | $444.9M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.21% | $381.4M | — | 2026-09-30 |
| 4 | MOAT VanEck Morningstar Wide Moat ETF | VanEck | 2.51% | $294.6M | $11.7B | 2026-10-26 |
| 5 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.39% | $248.2M | — | 2026-09-30 |
| 6 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.03% | $247.1M | $885.1B | 2026-10-26 |
| 7 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.03% | $227.4M | $810.0B | 2026-10-26 |
| 8 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.20% | $202.2M | — | 2026-10-26 |
| 9 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.29% | $133.5M | $46.7B | 2026-10-26 |
| 10 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 2.43% | $89.2M | $3.6B | 2026-10-26 |
| 11 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.14% | $79.5M | $57.8B | 2026-10-26 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.24% | $52.5M | — | 2026-09-30 |
| 13 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.03% | $51.4M | $183.4B | 2026-10-26 |
| 14 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.05% | $41.5M | $83.0B | 2026-10-26 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.05% | $41.0M | — | 2026-10-26 |
| 16 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.06% | $31.2M | $50.6B | 2026-10-26 |
| 17 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 2.52% | $28.8M | $1.1B | 2026-10-26 |
| 18 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.18% | $27.9M | $15.2B | 2026-10-26 |
| 19 | OAKM Oakmark U.S. Large Cap ETF | Nport | 2.49% | $26.1M | — | 2026-06-30 |
| 20 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.03% | $24.4M | $97.1B | 2026-10-26 |
| 21 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.06% | $23.7M | $38.7B | 2026-10-26 |
| 22 | VLUE iShares MSCI USA Value Factor ETF | iShares (BlackRock) | 0.20% | $18.4M | $9.3B | 2026-10-26 |
| 23 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.02% | $17.3M | — | 2026-05-31 |
| 24 | IUSV iShares Core S&P U.S. Value ETF | iShares (BlackRock) | 0.06% | $16.6M | $28.4B | 2026-10-26 |
| 25 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.04% | $16.3M | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
23.40
TTM Diluted EPS
$4.12
TTM Revenue
$8.51B
TTM Net Income
$806.70M
TTM Op. Cash Flow
$1.74B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $2.18B | $198.30M | $1.03 | $447.90M |
| Q1 '26 | 2026-03-31 | $2.09B | $238.20M | $1.22 | $359.20M |
| Q4 '25 | 2025-12-31 | $2.24B | $139.30M | $0.71 | $517.30M |
| Q3 '25 | 2025-09-30 | $2.00B | $230.90M | $1.16 | $418.80M |
| Q2 '25 | 2025-06-30 | $2.08B | $152.80M | $0.77 | $378.30M |
| Q1 '25 | 2025-03-31 | $1.91B | $181.90M | $0.91 | $382.70M |
| Q4 '24 | 2024-12-31 | $2.02B | $239.50M | $1.19 | $506.20M |
| Q3 '24 | 2024-09-30 | $1.82B | $249.10M | $1.23 | $395.80M |
| Q2 '24 | 2024-06-30 | $1.94B | $242.80M | $1.18 | $369.40M |
| Q1 '24 | 2024-03-31 | $1.89B | $172.40M | $0.84 | $228.00M |
| Q4 '23 | 2023-12-31 | $1.94B | $419.20M | $2.00 | $588.40M |
| Q3 '23 | 2023-09-30 | $1.75B | $162.70M | $0.77 | $337.60M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
23.40
P/B
1.50
P/S
2.23
EV/EBITDA
10.02
EV/Sales
2.92
ROE
6.4%
ROA
3.5%
Div Yield
1.03%
FCF Yield
9.20%
Debt/Equity
0.50
Current Ratio
—
Market Cap
$18.94B
as of 2026-10-28
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.75M
SI % of Float
5.13%
Days to Cover
4.39
Short Vol Ratio
67.8%
Free Float
189.80M
Float %
99.5%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-14